Evidence map›Paper›PMID 38788241›Full record

ArticleJournal of medicinal chemistry2024

Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists.

Ryan E Murphy, Pingyuan Wang, Saghir Ali, Hudson R Smith, Daniel E Felsing, Haiying Chen, Jia Zhou, John A Allen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Coumarin benzamide scaffold as potential 5-HTJournal of molecular modeling · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ryan E MurphyCenter for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.ORCID 0000-0003-0771-8800
Pingyuan WangCenter for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.ORCID 0009-0005-0368-5070
Saghir AliCenter for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
Hudson R SmithCenter for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
Daniel E FelsingCenter for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
Haiying ChenCenter for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
Jia ZhouCenter for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.ORCID 0000-0002-2811-1090
John A AllenCenter for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.

Funding

Translational Explorations in Substance Use DisordersT32DA007287 · NIDA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Kathryn A. Cunningham, Jonathan Dean Hommel · 1994 to 2026
$4.7M
Validation of GPR52 agonists as a therapeutic approach for stimulant use disordersU18DA052543 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ALLEN, JOHN A · 2020 to 2020
$237k
NIDA NIH HHS T32 DA007287NIDA NIH HHS U18 DA052543
6 · The paper itself

Abstract

Orphan GPR52 is emerging as a promising neurotherapeutic target. Optimization of previously reported lead

Indexed as

BenzamidesReceptors, G-Protein-CoupledAnimalsDrug DiscoveryHEK293 CellsHumansMiceRatsSignal TransductionStructure-Activity RelationshipBenzamidesGPR52 protein, humanReceptors, G-Protein-Coupled

Identifiers

PMID38788241
PMCPMC11441106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.